{"id":"W4385064330","doi":"10.1002/pbc.30584","title":"Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms","year":2023,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Astellas Pharma; National Institutes of Health; Incyte; bluebird bio; Leukemia and Lymphoma Society; Jazz Pharmaceuticals; Syndax Pharmaceuticals; CureSearch for Children's Cancer; St. Baldrick's Foundation; Servier; Amgen","keywords":"Medicine; Gemtuzumab ozogamicin; Oncology; Internal medicine; Clinical trial; Sorafenib; Myeloid leukemia; Hematopoietic stem cell transplantation; CD33; Disease; Hematology; Intensive care medicine; Stem cell; CD34","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004106172,0.001461461,0.001094751,0.002084607,0.001295442,0.005190343,0.002073749,0.008664695,0.1762456],"category_scores_gemma":[0.01221395,0.000591606,0.001147858,0.001838201,0.001577837,0.002862183,0.002992715,0.01069561,0.1303754],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003898726,"about_ca_system_score_gemma":0.01179189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002884246,"about_ca_topic_score_gemma":0.007251808,"domain_scores_codex":[0.9957299,0.0006888696,0.000232167,0.0006332663,0.001897784,0.0008180724],"domain_scores_gemma":[0.9846245,0.001630532,0.000707131,0.0008100538,0.005190479,0.007037343],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001948692,0.00001011722,0.000049265,0.00003885574,0.000002887391,0.00002336993,0.000003139178,0.00001351746,0.00005584335,0.001036629,0.9705422,0.02820467],"study_design_scores_gemma":[0.0000297918,0.00001488712,0.0002142918,0.0001306699,0.000002324568,0.0000603274,0.000006592361,0.0000160353,0.00002790675,0.0005769366,0.9989161,0.000004119037],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.0005147483,0.02604185,0.001227912,0.3813926,0.3664215,0.0002769216,0.002989396,0.0009663809,0.2201689],"genre_scores_gemma":[0.005679798,0.0467538,0.004513226,0.188662,0.1968503,0.0004891116,0.005508649,0.001074271,0.5504688],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.1762456,"threshold_uncertainty_score":0.5896002,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09014931244591472,"score_gpt":0.4150112182774019,"score_spread":0.3248619058314872,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}